These numbers are pulled directly from the manufacturer’s “JUQ‑470 Technical Data Sheet” (Version 1.2, released March 2023).
: "JUQ-470 is undoubtedly a step forward in tech innovation. While it's not without its challenges, the potential benefits are significant. As we learn more, it's clear that JUQ-470 could be a game-changer." JUQ-470
| Target | Type of inhibition | Reported IC₅₀ (nM) | Relevance in cancer | |--------|-------------------|-------------------|---------------------| | | ATP‑competitive | 12 ± 3 | Drives proliferation in breast, lung, and bladder cancers with FGFR1 amplification. | | VEGFR2 (vascular endothelial growth factor receptor 2) | ATP‑competitive | 18 ± 2 | Critical for angiogenesis; inhibition reduces tumor vascular supply. | | Additional off‑targets | Low‑nanomolar binding to PDGFRβ and c‑KIT (reported in broad kinase panels) | 45–90 | May contribute to broader antitumor activity but raise potential safety signals. | These numbers are pulled directly from the manufacturer’s